Salute e Benessere
Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of XOLAIR in Adults, PALFORZIA in Toddlers and Expected Entry of Viaskin Peanut Patches | DelveInsight
Discover which therapies are expected to grab the peanut allergy therapeutics market share @
The peanut allergy market dynamics are expected to change in the coming years. , administered orally, offers a convenient and accessible treatment option compared to , intradermal, and epicutaneous therapies, potentially enhancing patient adherence and ; has improved peanut allergy treatment by , helping prevent accidental anaphylaxis and offering meaningful protection for patients and families, while the , with XOLAIR as the sole approved treatment and only under evaluation, highlighting significant potential for growth, especially as in the allergy treatment space accelerate the development of novel therapies.
Furthermore, potential therapies are being investigated for the treatment of peanut allergy, and it is safe to predict that the treatment space will significantly impact the peanut allergy market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the peanut allergy market in the 7MM.
However, several factors may impede the growth of the peanut allergy market. Notable weakness in the peanut allergy landscape is the slow uptake of PALFORZIA, underdiagnosis of mild patients, , with remibrutinib being the only drug currently under evaluation for the 18–55 age group. This is compounded by the , highlighting a gap in therapeutic innovation that restricts treatment options and hinders progress in addressing diverse patient needs.
Additionally, the , ranging from , poses a significant threat by limiting affordability and access, thereby challenging its widespread adoption. Furthermore, i increase the risk of accidental exposure, complicating condition management and posing ongoing risks for individuals with peanut allergies.
Moreover, peanut allergy treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the peanut allergy market growth may be offset by , , , and a . In addition, the about the disease may also impact the peanut allergy market growth.
Managing peanut allergies requires a comprehensive approach, with strict avoidance of the allergen remaining the key method for preventing severe, potentially fatal anaphylactic reactions. However, recent clinical guidelines mark a significant change in prevention strategies by recommending the early introduction of peanut-containing foods between 4 to 6 months of age, even for infants at high risk. This proactive approach has been shown to greatly reduce the chances of developing a peanut allergy, replacing the older practice of strict avoidance.
While medications such as can be used during allergic reactions, it's important to note that they do not treat anaphylaxis directly. These are supportive treatments used alongside other interventions in managing anaphylactic episodes. Although allergen avoidance remains the foundation of care, innovative preventive measures are under development. One such method, oral immunotherapy, involves gradually increasing exposure to small amounts of peanut, and clinical trials have shown encouraging results.
Another promising desensitization technique is epicutaneous immunotherapy, where peanut protein is applied to the skin over time to help build tolerance. This form of therapy has improved peanut allergy management by increasing the reaction threshold, lowering the risk of accidental exposure, and providing patients with added protection and confidence.
Currently, are the only approved treatments for peanut allergy. PALFORZIA is authorized for children aged 1–3 and 4–17 years, while XOLAIR is approved for individuals aged 1 year and older. These peanut allergy therapies offer valuable options for both patients and healthcare professionals in managing peanut allergies.
To know more about peanut allergy treatment options, visit @
A robust pipeline of emerging therapies for peanut allergy is progressing, driven by innovative treatments with diverse mechanisms of action, such as , and the combination of . Among these, the stands out as a promising noninvasive option, offering ease of use and a strong safety profile, which may make it especially suitable for young children aged 1 to 7.
is an epicutaneous immunotherapy (EPIT) that delivers trace amounts of peanut protein via a skin patch to promote desensitization in allergic individuals. It has received both Fast Track and Breakthrough Therapy Designations from the US FDA. The therapy is currently being assessed in a Phase III clinical trial involving peanut-allergic children aged 4 to 7. DBV Technologies expects to share top-line data from the VITESSE trial (NCT05741476) in Q4 2025.
In March 2025 , DBV Technologies and the FDA aligned on key regulatory steps following written responses to a Type D IND meeting request. The FDA agreed that safety exposure data from the VITESSE Phase III trial in children aged 4–7 would be adequate to support a Biologics License Application (BLA) for this age group, potentially advancing the BLA submission to the first half of 2026. A separate BLA for children aged 1–3 is planned for the second half of 2026, contingent on the successful outcome of the COMFORT Toddlers Study.
is a next-generation immunotherapy that utilizes engineered peptides to specifically engage T cells and retrain the immune system, aiming to reverse allergic responses. It is currently in a Phase II clinical trial for children and adolescents with peanut allergies. In November 2024 , Aravax established a UK subsidiary at Oxford Science Park, marking a strategic step in its global expansion in food allergy treatment. Additionally, in October 2024 , the company completed patient enrollment for its Phase II study (AVX-201) evaluating PVX108.
is an oral, highly selective, covalent Bruton's Tyrosine Kinase (BTK) inhibitor being developed for a range of autoimmune and inflammatory conditions, including chronic spontaneous urticaria, myasthenia gravis, multiple sclerosis, food allergy, and hidradenitis suppurativa. It is currently in a Phase II clinical trial for adults with peanut allergy.
These new peanut allergy therapies, which act on different molecular targets and pathways, represent encouraging alternatives to existing treatments. Their development underscores a growing emphasis on more precise and targeted strategies for managing the complexities of peanut allergy
Additionally, the anticipated launch of these emerging therapies are poised to transform the peanut allergy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the peanut allergy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about peanut allergy drugs in development @
Peanut allergy is one of the most prevalent food allergies in children and has notably increased over recent decades. It results from an abnormal immune response involving IgE antibodies directed against peanut proteins, which can cause severe and potentially life-threatening anaphylactic reactions. Beyond the immediate health dangers, this allergy significantly affects the quality of life for both patients and their families.
Compared to other IgE-mediated food allergies, peanut allergy is associated with a higher incidence of anaphylaxis-related fatalities in emergencies. In individuals with this allergy, the initial exposure to peanut antigens activates Th2 cells that release cytokines, encouraging the production of IgE antibodies. These antibodies attach to Fce receptors on mast cells and basophils, sensitizing them.
Upon subsequent exposure, the allergen crosslinks the IgE on these primed cells, leading to degranulation and the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This response triggers vasodilation, increased vascular permeability, and inflammation, manifesting in allergic symptoms.
In addition to these biochemical processes, mechanical factors in the allergic microenvironment also influence immune activity. When diagnosing peanut and other food allergies, a detailed clinical history is essential to appropriately interpret test results. The most accurate diagnostic method is the double-blind, placebo-controlled food challenge (DBPCFC). However, skin prick testing (SPT) and measurement of specific IgE levels are commonly used first-line tools due to their speed and affordability.
The peanut allergy epidemiology section provides insights into the historical and current peanut allergy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The peanut allergy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving peanut allergy market trends @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key food allergy companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peanut allergy companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key food allergy companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lactose intolerance companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/peanut-allergy-market-set-to-grow-at-a-16-cagr-during-the-study-period-20202034-owing-to-current-usage-of-epinephrine-anticipated-usage-of-xolair-in-adults-palforzia-in-toddlers-and-expected-entry-of-viaskin-peanut-patches--302506497.html